Prognostic Value of p53 for Local Failure in Mastectomy-Treated Breast Cancer Patients

R. C. Zellars, S. G. Hilsenbeck, G. M. Clark, et al.
Abramson Cancer Center of the University of Pennsylvania
Last Modified: November 1, 2001

Share article

Reviewers: Li Liu, MD
Source: Journal of Clinical Oncology, Vol. 18, No 9, 1906-1913, (May) 2000


Randomized clinical trials have established that radiation therapy improves the local regional control and survival in selected breast cancer patients treated with mastectomy. However, only about 50% of patients will benefit from post-mastectomy irradiation and the remaining 50% still die with uncontrolled local-regional disease. Much effort has been made to identify breast cancer patients at greatest risk of local-regional failure and most likely to benefit from postmastectomy irradiation. Dr. Zellars and his colleagues examined the tumor suppressor gene p53 as a predictor of local-regional failure.

Materials and Methods

p53 levels were examined retrospectively in 1,530 breast cancer patients treated with mastectomy. In 259 patients, mastectomy was followed with adjuvant radiation therapy.


After a median follow-up of 62 months, the researchers found:

  • Patients with p53-positive tumors had a significantly higher recurrence rate, whether they received adjuvant radiation or not.
  • In patients not treated with radiation, the local failure rate was 9.1% with p53-negative tumors and 16.5% for p53-positive tumors.
  • In patients treated with radiation, the local failure rate was 9.3% with p53-negative tumors and 21.5% in p53-positive tumors.


In this study, p53-positive breast cancers were strongly associated with an increased risk of local recurrence after mastectomy, regardless of adjuvant radiation treatment. This finding may help physicians to identify a subgroup of breast cancer patients who are at greater risk of local-regional failure and who therefore may benefit from more aggressive local management.

Prognostic Value of p53 in Early Urothelial Cancers Unconfirmed

Aug 4, 2011 - In patients with pT1/T2N0M0 urothelial bladder cancer, the predictive value of p53 and the benefit of methotrexate, vinblastine, doxorubicin, and cisplatin adjuvant chemotherapy could not be demonstrated, according to a study published online Aug. 1 in the Journal of Clinical Oncology.

I Wish You Knew

How cancer patients have changed my life

View More

Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.

OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More